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Abstract
Malignant gliomas are one of the most devastating and incurable tumors. Sustained excessive angiogenesis by glioma cells
is the major reason for their uncontrolled growth and resistance toward conventional therapies resulting in high mortality.
Therefore, targeting angiogenesis should be a logical strategy to prevent or control glioma cell growth. Earlier studies have
shown that Asiatic Acid (AsA), a pentacyclic triterpenoid, is effective against glioma and other cancer cells; however, its
efficacy against angiogenesis remains unknown. In the present study, we examined the anti-angiogenic efficacy of AsA
using human umbilical vein endothelial cells (HUVEC) and human brain microvascular endothelial cells (HBMEC). Our results
showed that AsA (5–20 mM) inhibits HUVEC growth and induces apoptotic cell death by activating caspases (3 and 9) and
modulating the expression of apoptosis regulators Bad, survivin and pAkt-ser473. Further, AsA showed a dose-dependent
inhibition of HUVEC migration, invasion and capillary tube formation, and disintegrated preformed capillary network. AsA
also inhibited the VEGF-stimulated growth and capillary tube formation by HUVEC and HBMEC. Next, we analyzed the
angiogenic potential of conditioned media collected from human glioma LN18 and U87-MG cells treated with either DMSO
(control conditioned media, CCM) or AsA 20 mM (AsA20 conditioned media, AsA20CM). CCM from glioma cells significantly
enhanced the capillary tube formation in both HUVEC and HBMEC, while capillary tube formation in both endothelial cell
lines was greatly compromised in the presence of AsA20CM. Consistent with these results, VEGF expression was lesser in
AsA20CM compared to CCM, and indeed AsA strongly inhibited VEGF level (both cellular and secreted) in glioma cells. AsA
also showed dose-dependent anti-angiogenic efficacy in Matrigel plug assay, and inhibited the glioma cells potential to
attract HUVEC/HBMEC. Overall, the present study clearly showed the strong anti-angiogenic potential of AsA and suggests
its usefulness against malignant gliomas.
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Introduction
Neo-angiogenesis refers to the formation of new blood vessels
from existing parent vessels and is considered crucial for the
transition of tumors from a dormant to malignant state [1,2].
Angiogenesis is now established as one of the hallmarks of cancer,
and it is estimated to be responsible for over 90% of all cancer
deaths [3]. For example, malignant gliomas are considered
incurable largely due to sustained and excessive angiogenesis,
and approximately 77% of glioma patients die within the first year
of their diagnosis [4,5,6,7,8,9,10]. Infact, gliomas are among the
most vascularized human tumors, and excessive vasculature is
induced by several pro-angiogenic factors produced by glioma
cells [11,12]. Hence, one possible treatment strategy that may
improve glioma patient’s outcome is the use of angiogenesis-
targeting agents.
Vascular endothelial growth factor (VEGF), a diffusible
glycoprotein, is a widely over-expressed pro-angiogenic factor
in most solid cancers and plays a critical role in various steps
involved in angiogenesis including endothelial cell proliferation,
migration and tube formation [13,14]. VEGF secreted by tumor
cells interacts with VEGF receptors (VEGFRs) in endothelial cells
and stimulates downstream signaling molecules such as mitogen-
activated protein kinases (MAPKs) and Akt to promote the
growth, survival and migration of endothelial cells [15,16,17].
Therefore, inhibition of VEGF secretion by tumor cells as well as
VEGF regulated signaling in endothelial cells could be important
in targeting tumor angiogenesis. The U.S. Food and Drug
Administration (FDA) has recently approved Avastin, an antibody
against the VEGF receptor, for the treatment of various cancers
[18,19]. Avastin has shown promising pre-clinical and clinical
activity against metastatic colorectal cancer in combination with
fluorouracil [20,21]. In addition, it was also recently approved for
the treatment of recurrent gliomas [22,23]. However, the
randomized phase II BRAIN study showed that the median
survival rate after Avastin treatment is limited and it was only 2–3
months longer compared to other treatments [24]. Moreover,
Avastin use is costly and could cause serious side effects such as
gastrointestinal perforation and bleeding. Alternatively, we
suggest the use of agents that are small, non-toxic, safe,
affordable, and efficacious in inhibiting angiogenesis in gliomas
and other cancers. In this direction, present study examines the
anti-angiogenic efficacy of one such small molecule namely
Asiatic Acid (AsA).
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22745AsA is a pentacyclic triterpenoid derived from the tropical
medicinal plant Centella asiatica (family-Apiaceae). Beneficial effects
of AsA have been reported in wound healing, UV-induced
photoaging, glutamate- or b-amyloid-induced neurotoxicity and
hepatofibrosis [25]. Furthermore, there are numerous reports
suggesting the strong neuroprotective and anti-cancer efficacy of
AsA [26,27,28,29,30]. For example, AsA treatment has been
reported to induce apoptotic death in human hepatoma and
malignant glioma cells through enhancing the intracellular
calcium release [31,32]. In another study, Park et al. reported
that AsA induces apoptosis in melanoma cells through increasing
the levels of reactive oxygen species [33]. AsA as well as Centella
asiatica extract have also been shown to possess strong efficacy
against colon cancer cells [34,35]. Despite these widely described
anti-cancer properties, AsA has not been tested for its anti-
angiogenic potential. In the present study, for the first time, we
investigated the anti-angiogenic efficacy of AsA using human
umbilical vein endothelial cells (HUVEC) and human brain
microvascular endothelial cells (HBMEC). We also examined AsA
activity in inhibiting the pro-angiogenic effects of VEGF as well as
the conditioned medium from human glioma cells (LN18 and
U87-MG) using HUVEC and HBMEC. Our results clearly
showed that AsA moderately inhibits endothelial cell growth but
strongly induces apoptosis as well as inhibits VEGF- and glioma
conditioned media-induced tube formation and invasiveness in
endothelial cells.
Results
AsA inhibits growth and induces apoptotic cell death in
HUVEC
To determine the effect of AsA on endothelial cells, in the first
experiment HUVEC were treated with various doses of AsA (at 5,
10, 15 and 20 mM), and its effect on cell number and cell death
was analyzed as a function of time (6, 12, 24, and 48 h) by trypan
blue exclusion assay. As shown in figure 1A, AsA treatment (5–
20 mM) decreased the viable cell number (% of total cell number)
by 7–13% (p#0.0120.001), 11–24% (p#0.0120.001), 11–27%
(p#0.001) and 10–35% (p#0.0120.001) after 6, 12, 24 and 48 h
of treatment, respectively. AsA treatment also resulted in a dose-
Figure 1. AsA inhibits growth and induces apoptosis in HUVEC. A & B. HUVEC (4610
4 cells per well) were treated with DMSO or different
doses of AsA (5–20 mM) in complete HUVEC media for 6, 12, 24 and 48 h. At each treatment time, both adherent and non-adherent cells were
collected and processed for the determination of viable cell number and dead cells percentage as mentioned in ‘Materials and Methods’. C. HUVEC
were treated with DMSO or AsA (5–20 mM) for 24 h and analyzed for apoptotic cell population using annexin V/PI staining as detailed in ‘Materials
and Methods’. In panels A, B, & C, each bar represents the mean 6 standard deviation of three samples. These results were almost similar in two
independent experiments. *, p#0.001; #,p #0.01; $,p #0.05. D. HUVEC were treated with DMSO or AsA (20 mM) for 24 and 48 h. After each
treatment time, total cell lysates were prepared and analyzed for cleaved PARP, cleaved caspase 3, cleaved caspase 9, Bad, survivin, pAkt-ser473, and
total Akt by Western blotting as detailed in ‘Materials and Methods’. In each case, membrane was also stripped and reprobed with anti-a-tubulin
antibody to confirm equal protein loading.
doi:10.1371/journal.pone.0022745.g001
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to DMSO control, cell death with AsA treatment (5–20 mM) was
increased by 3–9% (p#0.05–0.001), 6–20% (p#0.01–0.001), 6–
22% (p#0.01–0.001), and 9–32% (p#0.01–0.001) after 6, 12, 24
and 48 h, respectively. Next, apoptotic cell percentage in the total
cell population was quantified by annexin V/PI dual staining.
Results showed that AsA induces apoptosis in HUVEC in a dose-
dependent manner especially at the highest AsA dose used i.e.
20 mM (Figure 1C). Accordingly, we used 20 mM dose of AsA to
further analyze its effect on apoptosis-related signaling molecules
in HUVEC. As shown in figure 1D, AsA treatment for 24 and
48 h resulted in PARP cleavage, which is a well established
biomarker for apoptotic death [36]. AsA also increased the
expression of cleaved caspase 3 and Bad after 24 and 48 h of
treatment, while increase in cleaved caspase 9 level was observed
only after 24 h of AsA treatment. Likewise, AsA also decreased the
levels of anti-apoptotic and pro-survival molecules namely survivin
and phosphorylated Akt-ser473 after 24 and 48 h of treatment
(Figure 1D). Overall, these results clearly showed that AsA
treatment decreases viability and induces apoptosis in HUVEC
through altering the expression of pro-apoptotic and anti-
apoptotic molecules.
AsA inhibits motility and capillary structure formation in
HUVEC
Endothelial cell motility i.e. migration/invasion is essential for
the formation of new blood vessels during neo-angiogenesis,
making it a critical event for tumor growth [37]. Accordingly, next
we studied the effect of AsA treatment on the migratory and
invasive properties of endothelial cells using wound-healing and
transwell assays, respectively (Figure 2A & 2B). As shown in
figure 2A, AsA treatment for 6 h inhibited the distance migrated
by HUVEC approximately by 28% (p#0.001), 43% (p#0.001),
51% (p#0.001) and 66% (p#0.001) at 5, 10, 15, and 20 mM
doses, respectively. Similarly, AsA treatment for 10 h inhibited the
number of HUVEC invaded through the matrigel by 25%
(p#0.001), 35% (p#0.001) and 59% (p#0.001) at 5, 10 and
15 mM doses, respectively (Figure 2B). For these studies, we
selected early time-points where we observed the least cytotoxicity
of AsA towards HUVEC (Figure 1A & 1B).
Another important step during neo-angiogenesis is the forma-
tion and merging of tubes by endothelial cells forming a complex
network of vessels and capillaries [38,39]. To understand AsA
effect on this biological event, we used two-dimensional matrigel
assay and examined AsA effect on tubular structure formation by
HUVEC. As shown in figure 2C, HUVEC plated on matrigel
formed a massive network of tubes after 6 h (i.e. DMSO treated
controls), which was disrupted by AsA treatment (5–20 mM)
(Figure 2C). We also measured the average tube length in each
case to quantify the inhibitory effect of AsA on the formation of
tubular network by HUVEC. As shown in the bar diagram, AsA
treatment inhibited the tube length approximately by 25%
(p#0.001), 55% (p#0.001), 60% (p#0.001) and 62% (p#0.001)
at 5, 10, 15, and 20 mM doses, respectively (Figure 2C). In another
related experiment, we examined the effect of AsA treatment on
preformed tubes by HUVEC, where we added AsA (5–20 mM)
after HUVEC had already formed the tubular network on
matrigel (after 10 h). In this experimental condition too, AsA
treatment significantly disrupted the tubular network formed by
HUVEC (Figure 2D). Quantification of tube length in this assay
showed that AsA treatment inhibits the tube length by 36%
(p#0.001), 43% (p#0.001), 45% (p#0.001) and 53% (p#0.001) at
5, 10, 15, and 20 mM doses, respectively (Figure 2D).These results
clearly showed that AsA treatment inhibits motility and tubular
structure formation as well as disrupts preformed capillary tubes
by HUVEC.
AsA inhibits VEGF-stimulated growth and capillary
structure formation in HUVEC
VEGF is the most important pro-angiogenic factor which is
known to enhance proliferation, survival, and tube formation by
endothelial cells [13]. Therefor e ,w en e x ts t u d i e dt h ee f f e c to f
AsA on VEGF-stimulated cell growth and cell death in
HUVEC. In this study, HUVEC grown under 0.5% serum
conditions were treated with 10 ng/ml VEGF and various
concentrations of AsA (5–20 mM). Cell number and cell death
were analyzed by trypan blue exclusion assay after 12 h of AsA
treatment. As shown in figure 3A, VEGF addition significantly
enhanced the HUVEC growth (p#0.001), which was inhibited
by AsA in a dose-dependent manner. In comparison to VEGF
alone, AsA at 5, 10, 15 and 20 mMd o s e sd e c r e a s e dt h eV E G F -
stimulated HUVEC number by 17% (p#0.001), 26%
(p#0.001), 52% (p#0.01) and 72% (p#0.001), respectively
(Figure 3A). AsA treatment also resulted in a dose-dependent
increase in HUVEC death. As shown in figure 3B, cell death
with AsA treatment increased by 1.8 fold (p#0.001), 2.6 fold
(p#0.001), 4.3 fold (p#0.001) and 4.6 fold (p#0.001) at 5, 10,
15 and 20 mMd o s e sr e s p e c t i v e l y .
Next, we investigated the effect of AsA treatment on VEGF-
stimulated tube formation in HUVEC. As shown in figure 3C,
VEGF presence significantly enhanced the tubular network
formation by HUVEC compared to HUVEC plated on matrigel
under 0.5% serum containing HUVEC media alone; however,
AsA treatment strongly inhibited the VEGF-stimulated tubular
network formation by HUVEC (Figure 3C), and tube length
measurement showed that AsA treatment inhibited the tube length
approximately by 54% (p#0.001), 68% (p#0.001), 78%
(p#0.001) and 82% (p#0.001) at 5, 10, 15 and 20 mM doses,
respectively (Figure 3C). These results clearly showed that AsA
strongly targets VEGF-stimulated cell proliferation and tubular
structure formation in HUVEC.
AsA inhibits VEGF-stimulated growth and capillary
structure formation in HBMEC
In order to rule out that the observed effect of AsA on VEGF-
stimulated proliferation and tube formation is limited to HUVEC,
we also investigated AsA effect on another endothelial cell line
isolated from human brain i.e. HBMEC. MTT assay results
showed that AsA (5–40 mM) decreases cell viability of HBMEC by
2–88% (p#0.05–0.001) and 12–90% (p#0.01–0.001) after 6 and
12 h of treatment respectively (Figure 4A). In this assay, the
inhibitory effect of AsA on the viability of HBMEC was maximum
at higher dose of 40 mM. AsA treatment also inhibited the VEGF-
stimulated growth of HBMEC by 8% (p#0.01), 19% (p#0.001),
31% (p#0.001), 54% (p#0.05) and 66% (p#0.01) at 5, 10, 15, 20
and 40 mM doses respectively (Figure 4B).
Further, we examined AsA effect on VEGF-stimulated tube
formation by HBMEC using the standard two-dimensional
matrigel assay. As shown in figure 4C, HBMEC plated on
matrigel formed a massive network of tubes (i.e. DMSO treated
controls) and thickness of the tubes formed by HBMEC was much
stronger than the HUVEC. However, AsA treatment disrupted
VEGF-stimulated tubular network formation by HBMEC in a
dose-dependent manner (Figure 4C). Tube length measurement
revealed that AsA treatment inhibits VEGF-stimulated tube length
approximately by 39% (p#0.001), 53% (p#0.001), 57%
(p#0.001) and 62% (p#0.001) at 5, 10, 15 and 20 mM doses,
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effect of AsA on endothelial is not cell line specific.
AsA treatment strongly inhibits human glioma
cell-induced angiogenesis in vitro
Gliomas are highly vascularized tumors and secrete large amounts
of pro-angiogenic factors, which act in a paracrine manner to promote
endothelial cell survival and tubular structure formation [12]. Hence,
targeting the expression and secretion of pro-angiogenic factors such
as VEGF in malignant gliomas could be a promising strategyto inhibit
the growth and progression of glioma. Accordingly, we next
performed in vitro co-culture studies to assess the effect of AsA
treatment on the potential of glioma cells to promote angiogenesis. In
this study, LN18 and U87-MG human glioma cells were treated with
AsA at 20 mM doses for 24 h, thereafter, media was removed and cells
were washed with 0.5% serum media and incubated for additional
Figure 2. AsA inhibits motility and capillary-structure formation in HUVEC. A. Effect of AsA treatment on the migratory potential of HUVEC
was analyzed through wound healing assay. Representative photomicrographs of initial and final wounds are shown at 100x magnification and
migration distance was measured as detailed in ‘Materials and Methods’. Cell migration distance data shown are mean 6 standard deviation of three
samples for each treatment. B. Effect of AsA treatment on the invasive potential of HUVEC was examined using invasion chambers as detailed in
‘Materials and Methods’. Cell invasion data shown are mean 6 standard deviation of three samples for each treatment. C. Effect of AsA on the tube
formation of HUVEC was examined by plating HUVEC on the matrigel. After 6 h, tubular structures were photographed at 100x magnification and
tube length was measured as described in ‘Materials and Methods’. Tube length data is presented as mean 6 standard deviation of three samples for
each treatment. D. Effect of AsA on the pre-formed tubes in HUVEC was analyzed and tube length was measured as detailed in ‘Materials and
Methods’. Tube length data shown are mean 6 standard deviation of three samples for each treatment. These results (A–D) were similar in 2–3
independent experiments. *, p#0.001.
doi:10.1371/journal.pone.0022745.g002
Anti-Angiogenic Efficacy of Asiatic Acid
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e2274512 h in 0.5% serum media without the presence of DMSO or AsA.
Subsequently, conditioned media was collected, centrifuged and
labeled as control conditioned media (from DMSO treated controls,
CCM) or AsA conditioned media (from AsA 20 mM treated samples,
AsA20CM). After collection of conditioned media, both LN18 and
U87-MG cells were trypsinized and counted using haemocytometer
and total cell lysate was prepared. As shown in figure 5A, under the
described experimental conditions, AsA treatment marginally de-
creased the live cells number in both the glioma cell lines (LN18 and
U87-MG). We preferred such experimental conditions to dissect out
anti-angiogenic effects of AsA and to establish that anti-angiogenic
effects of AsA are not due to its cytotoxicity towards glioma cells. To
fulfill that objective, we also normalized the volume of conditioned
media to be used in angiogenesis assay with respective cell numbers
from DMSO or AsA treated LN18 and U87-MG cells. Next, we
compared the VEGF level in CCM and AsA20CM from both LN18
and U87-MG cells by immunoblotting, and found that AsA20CM
from both LN18 and U87-MG cells has lower level of VEGF
compared to CCM (Figure 5B, left panel). Under similar experimental
conditions, cellular VEGF was also lower in LN18 and U87-MG cells
that were earlier exposed to AsA (Figure 5B, right panel). We also
observedthat CCMfromLN18 cells strongly increasestube formation
by both HUVEC and HBMEC, while in HUVEC and HBMEC
plated with AsA20CM, tube formation was completely diminished
both in terms of tubular network quality and tube length (Figure 5C).
We observed a similar increase in tube formation by CCM collected
Figure 3. AsA inhibits VEGF-stimulated cell growth and capillary tube formation in HUVEC. HUVEC were grown under 0.5% serum
conditions and treated with or without VEGF (10 ng/mL) and various doses of AsA (5–20 mM) for 12 h as described in Materials and Methods. After
12 h, both adherent and non-adherent cells were collected and processed for determination of total cell number (A) and dead cells percentage (B)a s
mentioned in ‘Materials and Methods’. C. HUVEC with or without VEGF (10 ng/mL) in 0.5% serum media were placed in 24-well plates coated with
Matrigel and treated with AsA at indicated doses. After 10 h tubular structures were photographed at 100x magnification and tube length was
measured as detailed in ‘Materials and Methods’. These results (A–C) were similar in 2–3 independent experiments. Each bar is representative of mean
6 standard deviation of three samples for each treatment. *, p#0.001; #,p #0.01.
doi:10.1371/journal.pone.0022745.g003
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HBMEC to form tubular networks in the presence of AsA20CM was
significantly reduced (Figure 5D). Whereas the effect of AsA on other
angiogenic factors remains unstudied, the results from our completed
studies clearly indicate that AsA treatment could inhibit VEGF
secretion by LN18 and U87-MG cells; thereby it could inhibit the pro-
angiogenic effects of these glioma cells.
AsA inhibits glioma cell-induced chemotactic motility of
endothelial cells
As mentioned above, glioma cells secrete large amounts of
pro-angiogenic factors and attract endothelial cells to enhance
neo-angiogenesis [11]. Our analysis of VEGF expression level in
the conditioned media of glioma cells suggested that AsA
decreases the secretion of VEGF from glioma cells. Hence, in
conjunction with this finding, our next aim was to examine
whether AsA could inhibit the migration of endothelial cells
towards glioma. To study this, we used the transwell migration
a s s a yb yp l a t i n ge n d o t h e l i a lc e l l si nt h eu p p e rc h a m b e ra n d
glioma cells in the lower chamber, and glioma cells were treated
with AsA at 20 and 40 mM doses. Under these experimental
conditions, we observed that the presence of LN18 glioma cells
in the lower chambers results in higher invasion of HUVEC and
H B M E Ct h r o u g hm a t r i g e ll a y e rc o m p a r e dt oo n l y0 . 5 %s e r u m
LN18 media in the lower chamber (Figure 6A & 6B). In the
presence of AsA (20 and 40 mM), the potential of glioma cells to
Figure 4. AsA inhibits growth and capillary tube formation in HBMEC. A. HBMEC (1610
3 per well) were seeded in a 96-well plates in
complete media and next day treated with DMSO or AsA (5–40 mM) and cell viability was determined at 6 and 12 h after AsA treatment through MTT
assay. B. HBMEC were grown under 0.5% serum conditions and treated with or without VEGF (10 ng/mL) and various doses of AsA (5–40 mM) for
12 h. The cell viability was determined by MTT assay. C. HBMEC (4610
4 per well) with or without VEGF (10 ng/mL) in 0.5% serum media were placed
in 24-well plates coated with Matrigel and treated with AsA at indicated doses. After 10 h, tubular structures were photographed at 100x
magnification and tube length was measured as described in ‘Materials and Methods’. Tube length data is presented as mean 6 standard deviation
of three samples for each treatment. *, p#0.001; #,p #0.01; $,p #0.05.
doi:10.1371/journal.pone.0022745.g004
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22745Figure 5. AsA inhibits human glioma cell-induced angiogenesis in vitro. A. LN18 and U87-MG human glioma cells were treated with AsA at
20 mM doses for 24 h, media was removed, washed with 0.5% serum media and incubated for an additional 12 h in 0.5% serum media without the
presence of DMSO or AsA. Subsequently, both LN18 and U87-MG cells were trypsinized, and counted using haemocytometer as detailed in ‘Materials
and Methods’. B. VEGF expression in CCM (control conditioned media) and AsA20CM (AsA20 conditioned media) or total cell lysates collected from
LN18 and U87-MG cells (detailed in ‘Materials and Methods’) was analyzed by Western blotting. The loading volume for conditioned media in each
case was normalized with respective cell number. Densitometric values presented below the bands are ‘fold change’ compared to respective
controls. AsA20-T/W refers to the group, where glioma cells were treated with AsA 20 mM dose for 24 h and then AsA was washed-out and cell lysates
were prepared after 12 h. C&D .HUVEC or HBMEC (4610
4 per well) were seeded in 24-well plates coated with matrigel and treated with CCM or
AsA20CM from LN18 cells or U87-MG cells for 10 h and tube formation assay was performed as described in ‘Materials and Methods’. In this
experiment, HUVEC or HBMEC incubated with 0.5% serum containing LN18 or U87-MG media served as a negative control. Tubular structures were
photographed at 100x magnification and tube length was measured as described in ‘Materials and Methods’. Tube length data is presented as mean
Anti-Angiogenic Efficacy of Asiatic Acid
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22745attract HUVEC and HBMEC through matrigel layer was
significantly compromised. As shown in figure 6A, AsA
treatment (20 and 40 mM) of LN18 cells resulted in 33% and
51% reduction in the migration of HUVEC towards LN18 cells.
Similarly, AsA treatment (20 and 40 mM) of LN18 cells resulted
in 11% and 61% reduction in the migration of HBMEC
towards LN18 cells (Figure 6B). Overall, these results clearly
showed that AsA treatment inhibits the glioma cell-induced
chemotactic motility of endothelial cells.
AsA inhibits cellular and secreted levels of VEGF in
glioma cells
Next, we examined AsA effect on VEGF level in LN18 and
U87-MG cells. As shown in figure 7A, AsA treatment for 24
and 48 h resulted in significant reduction in the VEGF protein
level in total cell lysates of both LN18 and U87-MG cells.
Since VEGF is actively released by glioma cells, we also
examined the effect of AsA treatment on secreted VEGF in the
media. ELISA quantitation showed that AsA treatment
decreases secreted VEGF level in LN18 and U87-MG cells
by 42% (p#0.001) and 28% (p#0.01), respectively, which was
further confirmed by Western blotting for the secreted VEGF
in the media (Figure 7B). Together, these results clearly show
that AsA inhibits VEGF levels both cellular and secreted in
glioma cells.
AsA treatment inhibits VEGF-stimulated angiogenesis in
vivo
To address the in vivo anti-angiogenic effect of AsA, we
employed the well established Matrigel plug assay. As shown in
figure 7C, VEGF presence in the Matrigel plug induced strong
vascularity and appeared dark red with blood. The AsA addition
in the Matrigel plugs blocked the VEGF-stimulated vascularity in
a dose-dependent manner (Figure 7C), supporting the strong anti-
angiogenic efficacy of AsA in vivo.
Discussion
Malignant gliomas are the most common brain tumors and are
associated with high mortality. Malignant gliomas are resistant to
conventional treatment methods and have poor prognosis mainly
because of sustained uncontrolled angiogenesis and resultant high
tumor mass [11]. It is difficult to remove these tumors surgically
without damaging normal nerve tissues. The current radioactive
and chemotherapeutic regimens also kill non-specifically many
functional and non-cancerous cells in the brain, which might
adversely impair different functions of the body. These frightening
details warrant immediate alternative strategies to prolong and
improve the quality of life of glioma patients. Preventing or
inhibiting angiogenesis in glioma using non-toxic and effective
phytochemicals could be a useful strategy in this direction. One of
6 standard deviation of three samples for each treatment. The volume for CCM/AsA20CM used in tube formation assay was normalized with
respective cell number shown in panel A. *, p#0.001.
doi:10.1371/journal.pone.0022745.g005
Figure 6. AsA inhibits glioma cells induced chemotactic motility of endothelial cells. A & B. HUVEC or HBMEC (3610
4 per well) were
seeded in the upper chamber of a Transwell plate with 0.5% serum media. In the lower chamber, LN18 cells (3610
4 cells per well) were treated with
DMSO or AsA 20 mM in 0.5% serum media as described in ‘Materials and Methods’. HUVEC and HBMEC migrated through the matrigel layer were
stained and quantified after 10 h and 22 h of their plating in the upper chamber respectively. Cell invasion data shown are mean 6 standard
deviation of three samples for each treatment. *, p#0.001; $,p #0.05.
doi:10.1371/journal.pone.0022745.g006
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AsA. AsA has a long history of use against numerous neurological
disorders with practically no side effects and its use has been shown
to improve the physical performance and health-related quality of
life [40,41]. Importantly, oral administration of AsA has been
reported to have good plasma availability in humans and there is
also sufficient evidence of its reach to brain tissue [30,40,41,
42,43,44,45]. In the present work, for the first time, employing in
vitro co-culture study models we demonstrated the usefulness of
AsA against the pro-angiogenic effects of gliomas.
Tumor microenvironment refers to complex cellular and
extracellular components surrounding tumor cells at each stage
of carcinogenesis [46]. Endothelial cell represent one of the critical
cellular elements in the tumor microenvironment that plays a
crucial role in the growth and progression of cancer through
controlling angiogenesis [46,47]. Recent literature suggests that
anti-angiogenic strategy targeting endothelial cells in the tumor
microenvironment could be important as endothelial cells are
generally non-transformed and are considered less prone to
acquire drug resistance [47,48,49]. Therefore, use of nontoxic
agents that could effectively target endothelial cells as well as the
resultant pathological angiogenesis in the tumor microenviron-
ment could be important in the prevention as well as treatment of
cancers. In the present study, AsA treatment strongly inhibited the
growth, tube formation as well as invasion/migration in
endothelial cells, thereby highlighting its importance as a novel
anti-angiogenic agent.
Cell survival is maintained by a delicate balance between anti-
apoptotic and pro-apoptotic stimuli. Results from the present
study showed that AsA treatment increases the expression of pro-
apoptotic molecules (caspase 3, caspase 9 and Bad) while
decreasing the expression of pro-survival and anti-apoptotic
molecules such as phosphorylated Akt and survivin. Even though
the present study was not designed to understand the sequence of
signaling events in endothelial cells following AsA treatment,
earlier studies have shown that serine/threonine kinase Akt
phosphorylates and prevents the pro-apoptotic action of Bad
[50]. Furthermore, the role of Akt has been reported in caspases
inactivation both directly through phosphorylating caspases and
indirectly through promoting the expression of anti-apoptotic
molecules such as survivin [50,51]. More definite studies are still
required to understand the mechanism/s underlying AsA-induced
apoptosis in endothelial cells.
A large number of pro- and anti-angiogenic cellular factors
regulate angiogenesis in gliomas. Among them, VEGF has been
implicated as a major paracrine mediator in the pathogenesis of
gliomas and it has been shown to directly contribute to
angiogenesis and blood brain barrier breakdown [12]. VEGF
Figure 7. AsA reduces VEGF level (both cellular and secreted) in glioma cells and strongly inhibits VEGF-stimulated angiogenesis in
vivo. A. LN18 and U87-MG cells were treated with DMSO or AsA (20 mM) for 24 and 48 h. After each treatment time, cell lysates were prepared and
analyzed for VEGF by Western blotting as described in ‘Materials and Methods’. Membranes were stripped and reprobed with anti- a-tubulin antibody
to confirm equal protein loading. Densitometric values presented below the bands are ‘fold change’ compared to respective control after
normalization with loading control. B. In LN18 and U87-MG cells, media was collected 24 h after AsA treatment (20 mM) and analyzed for secreted
VEGF level by Western blotting and ELISA as detailed in ‘Materials and Methods’. C. Nude mice were subcutaneously injected with 0.5 mL Matrigel
containing 100 ng/mL VEGF, 100 units of heparin and different doses of AsA (12.5, 25 and 50 mg/mL). Matrigel plugs were removed after 5 days and
representative pictures are shown. *, p#0.001; #,p# 0.01.
doi:10.1371/journal.pone.0022745.g007
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tyrosine kinase, which promotes several events required for
angiogenesis including endothelial cell survival, proliferation,
migration and tube formation [15,16]. Currently, more than 20
agents targeting VEGF, VEGFR or other members of this
signaling cascade have been either approved for cancer treatment
or undergoing clinical (phase I–III) studies. In the present study,
we found that AsA effectively inhibits VEGF-stimulated prolifer-
ation and tube formation in HUVEC and HBMEC. Further, we
also observed that AsA inhibits VEGF expression both cellular and
secreted in glioma cells; thereby inhibiting pro-angiogenic effects
of glioma cells. Further studies are needed to define the effect of
AsA on other important anti-angiogenic and pro-angiogenic
factors, but these completed studies suggest the important role of
VEGF in the anti-angiogenic efficacy of AsA.
In summary, the present study shows that AsA- (a) inhibits
HUVEC and HBMEC proliferation, invasion, migration and tube
formation; (b) inhibits VEGF-stimulated cell proliferation and tube
formation; (c) induces apoptosis by increasing expression of pro-
apoptotic signaling molecules, while decreasing the expression of
anti-apoptotic signaling molecules; (d) inhibits VEGF expression in
glioma cells; and (e) strongly inhibits angiogenesis in vivo.I n
addition, our study provided evidence that AsA could inhibit the
glioma cell conditioned media-induced tube formation as well as
migration of endothelial cells towards glioma cells by inhibiting the
secretion of VEGF from glioma cells. Taken together, our findings
suggest that the natural agent AsA could potentially be beneficial
as an anti-angiogenic agent and might be a promising chemopre-
ventive agent against gliomas.
Materials and Methods
Reagents
Synthetic AsA, with structure confirmed by infrared and proton
NMR spectra, was obtained from Sigma-Aldrich (St Louis, MO,
USA). The stock solution of AsA was prepared in DMSO and
stored at 220uC as small aliquots. Lyophilized recombinant
human VEGF was purchased from Invitrogen/Gibco (Camarillo,
CA, USA). Matrigel and invasion chambers were purchased from
BD Biosciences (New Bedford, MA, USA). Heparin sodium salt
was from Tocris Bioscience (Park Ellisville, MO, USA). Primary
antibodies for cleaved caspase 3, cleaved caspase 9, cleaved
poly(ADP-ribose)polymerase (cPARP), pAkt-ser473, total Akt,
Bad, and anti-rabbit peroxidase-conjugated secondary antibody
were obtained from Cell Signaling (Beverly, MA, USA). Survivin
antibody was from Novus (Littleton, CO, USA). VEGF antibody
was from abcam (Cambridge, MA, USA). Human VEGF ELISA
kit was from R & D systems (Minneapolis, MN, USA). a-tubulin
antibody was from Neomarkers (Fremont, CA, USA). ECL
detection system and anti-mouse HRP conjugated secondary
antibody were from GE Healthcare (Buckinghamshire, UK). Bio-
Rad detergent-compatible protein assay kit was from Bio-Rad
Laboratories (Hercules, CA, USA). All other reagents were
obtained in their highest purity grade available commercially.
Cell lines and cell culture
HUVEC were from Lonza (Walkersville, MD, USA) and were
cultured in EGM-2 Bulletkit from Lonza (Walkersville, MD, USA)
under standard culture conditions (37uC, 95% humidified air and
5% CO2). HBMEC were obtained from ScienCell Research
Laboratories (Carlsbad, CA, USA) and cultured in endothelial cell
media (ScienCell Research Laboratories, Carlsbad, CA, USA).
LN18 and U87-MG human glioma cells were from the American
Type Culture Collection (ATCC) and cultured in ATCC-
formulated Dulbecco’s Modified Eagle’s Media supplemented
with 5% fetal bovine serum (FBS) and Minimum Essential Media,
Eagle with Earle’s Balanced Salt Solution plus 10% FBS
respectively at 37uC under standard culture conditions.
Cell viability assay
HUVEC (4610
4 cells per well) were seeded in complete
HUVEC media (EBM-2 basal media containing FBS and growth
supplements) in six-well plates. The next day, cells were treated
with different doses of AsA (5, 10, 15 and 20 mM) for 6, 12, 24 and
48 h. At the end of each treatment time, total cells were collected
by a brief trypsinization and counted using haemocytometer.
Trypan blue dye was used for assessing dead cells. In another
experiment, HUVEC (4610
4 cells per well) were grown under
0.5% serum EBM-2 media and treated with or without VEGF
(10 ng/mL) and various doses of AsA for 12 h. At the end of
treatment, cell number and cell death were assessed by trypan blue
dye using a haemocytometer. To determine cell viability of
HBMEC, we used MTT reagent and absorbance was measured
by spectrophotometer at 540 nm.
Quantitative apoptosis assay
AsA effect on apoptosis in HUVEC was quantified by annexin
V/PI staining and flow cytometry. Briefly, after AsA treatment (5,
10, 15 and 20 mM for 24 h), cells were collected and washed with
PBS twice, and subjected to annexin V and PI staining using
Vybrant Apoptosis Assay Kit 2 following the protocol provided by
the manufacturer (Invitrogen, Eugene, OR, USA). After staining,
flow cytometry was performed for the quantification of apoptotic
cells using the flow cytometry core facility at University of
Colorado Cancer Center.
Endothelial cell migration assay
HUVEC were allowed to grow to full confluence in six-well
plates. Subsequently, cells were wounded by pipette tips and
washed twice with media to remove detached cells, and
photomicrographs of initial wounds were taken using Canon
Power Shot A640 digital camera (at 100x magnification).
Thereafter, cells were treated with DMSO or 5-20 mM doses of
AsA. Experiment was terminated as soon as wound was
completely filled in DMSO treated controls (after 6 h) and
photomicrographs of final wounds were taken for each group.
Initial and final wound sizes were measured using AxioVision
Rel.4.7 software, and difference between the two was used to
determine migration distance using the formula: Initial wound size
minus final wound size divided by 2.
Endothelial cell Transwell migration assay
The chemotactic motility of HUVEC was determined using
Transwell migration chambers (BD Biosciences) with 6.5-mm-
diameter polycarbonate filters (8-mm pore size) as described
previously [47]. In brief, the bottom chambers were filled with
750 mL of EBM-2 media containing all supplements. HUVEC
(3610
4 per well) were seeded in top chambers with DMSO or
various doses of AsA (5, 10 and 15 mM) in 500 mL EBM-2 media
with 0.5% serum. Cells were allowed to migrate for 10 h. Non-
migrated cells were removed with cotton swabs, and migrated cells
were fixed with ice cold methanol and stained with Haematoxylin
& Eosin. Images were captured using Cannon Power Shot A640
camera on Zeiss inverted microscope with magnification x100 and
invasive cells were quantified by manual counting. In another
experiment, we plated LN18 cells in the bottom chamber (DMEM
media with 0.5% serum) and treated with either DMSO or AsA.
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or ECM media respectively with 0.5% serum and their invasion
was studied at defined time points following the protocol detailed
above.
Endothelial cell capillary-like tube formation assay
To examine the effect of AsA on in vitro angiogenesis, tube
formation assay was performed as described previously [47]. In
this assay, we employed two study protocols. In the first protocol,
growth factor-reduced matrigel was pipetted into pre-chilled 24-
well plates (150 mL matrigel per well) and polymerized for 45 min
at 37uC. HUVEC (4610
4 per well) in complete media were
simultaneously seeded with DMSO or AsA (5, 10, 15 and 20 mM)
in matrigel coated plates. After 6 h of incubation, tubular
structures were photographed. In the second protocol, DMSO
or AsA (5, 10, 15 and 20 mM) treatment was carried out 10 h after
HUVEC seeding (when capillary network was already formed). In
this case, tubular structures were photographed after 22 h of AsA
exposure. Further to check the effect of AsA on VEGF-stimulated
tube formation, HUVEC or HBMEC were collected, washed
twice with 0.5% serum media and then seeded on matrigel pre-
coated plates with or without VEGF (10 ng/mL) along with
DMSO or AsA (5, 10, 15 and 20 mM). After 10 h, tubular
structures were photographed. In all these experiments, images
were captured using Cannon Power Shot A640 camera on Zeiss
inverted microscope with magnification x100 and tube length was
quantified by AxioVision Rel.4.7 software.
Conditioned media collection for experimentation
Glioma cells (LN18 and U87-MG cells) were treated with
DMSO or 20 mM dose of AsA for 24 h in complete media
conditions. Thereafter, media was removed and plates were
washed twice with 0.5% serum media and incubated for another
12 h with 0.5% serum media. Subsequently, conditioned media
was collected, centrifuged and labeled as control conditioned
media (CCM) or AsA20 conditioned media (AsA20CM) and
stored at 280uC until further use. For tube formation assay, we
optimized a ratio of 75:25 for CCM/AsA20CM and HUVEC/
HBMEC media. The glioma cell media with 0.5% serum served as
negative control in these experiments.
Western blotting
To determine the effects of AsA on apoptotic molecules,
HUVEC were treated with DMSO or AsA for 24 and 48 h and
then whole-cell extracts were prepared in lysis buffer (10 mmol/L
Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1% Triton X-100,
1 mmol/L EDTA, 1 mmol/L EGTA, 0.3 mmol/L phenyl-
methylsulfonyl fluoride, 0.2 mmol/L sodium orthovanadate,
0.5% NP40, and 5 units/mL aprotinin) as described earlier
[52]. 60 mg of cellular protein from each sample was denatured in
2X SDS-PAGE sample buffer and resolved on 8–16% Tris-
glycine gels. The separated proteins were transferred to a
nitrocellulose membrane followed by blocking with 5% nonfat
milk powder (w/v) in Tris-buffered saline (10 mM Tris–HCl,
pH 7.5, 100 mM NaCl, 0.1% Tween-20) for 1 h at room
temperature. After blocking, the membranes were probed with
desired primary antibodies for 2 h at room temperature and then
overnight at 4uC followed by appropriate peroxidase-conjugated
secondary antibody for 1 h at room temperature and visualized
by ECL detection system. In each case, blots were subjected to
multiple exposures on the film to make sure that the band density
is in the linear range. Autoradiograms/bands were scanned and
as needed, the mean density of bands was determined using
Adobe Photoshop 6.0 (Adobe Systems, Inc., San Jose, CA, USA).
To ensure equal protein loading, each membrane was stripped
and reprobed with a-tubulin antibody. Wherever applicable, the
densitometric value for each band was normalized with respective
loading control value i.e. a-tubulin. In another experiment, to
determine the effect of AsA on VEGF expression, LN18 and
U87-MG cells were treated with AsA at 20 mM for 24 and 48 h
and then total-cell extracts were prepared in lysis buffer as
described above. In order to assess the effect of AsA on VEGF
secretion from glioma cells, media was collected under the above
described treatment condition, centrifuged and used for Western
blot analysis.
ELISA assay for VEGF
ELISA assay for quantitative estimation of VEGF in the media
from LN18 and U87-MG cells was done as per vendor’s protocol
(R & D systems).
In vivo Matrigel plug assay
Effect of AsA on VEGF-stimulated angiogenesis in vivo was
determined by Matrigel plug assay. Briefly, nude mice were
subcutaneously injected with 0.5 mL of Matrigel containing
100 ng/mL VEGF, 100 units of heparin and different doses of
A s A( 1 2 . 5 ,2 5a n d5 0mg/mL). After 5 days, mice were sacrificed
and the skin of each mouse was pulled back to expose the
Matrigel plug. Pictures of Matrigel plugs were taken using
Canon Power Shot A640 digital camera. For each treatment,
there were two matrigel plugs and the experiment was repeated
once.
Statistical analysis
All statistical analyses were carried out with Sigma Stat software
version 2.03 (Jandel scientific, San Rafael, CA). Mean and
standard deviation were used to describe the quantitative data.
One-way ANOVA followed by Tukey’s test was used for multiple
comparisons and a statistically significant difference was consid-
ered at p#0.05.
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